Filing Details

Accession Number:
0001104659-21-093670
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2021-07-19 21:02:01
Reporting Period:
2021-01-14
Accepted Time:
2021-07-19 21:02:01
Original Submission Date:
2021-01-19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1737953 Replimune Group Inc. REPL Biological Products, (No Disgnostic Substances) (2836) 822082553
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1744425 Pamela Esposito C/O Replimune Group, Inc., 500 Unicorn
Park
Woburn MA 01801
Chief Business Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-01-14 20,000 $1.01 195,994 No 4 M Direct
Common Stock Disposition 2021-01-14 20,000 $45.02 175,994 No 4 S Direct
Common Stock Acquisiton 2021-01-15 29,273 $1.01 205,267 No 4 M Direct
Common Stock Disposition 2021-01-15 29,273 $43.58 175,994 No 4 S Direct
Common Stock Acquisiton 2021-01-19 5,727 $1.01 181,721 No 4 M Direct
Common Stock Disposition 2021-01-19 600 $43.24 181,121 No 4 S Direct
Common Stock Disposition 2021-01-19 5,127 $42.38 175,994 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2021-01-14 20,000 $0.00 20,000 $1.01
Common Stock Employee Stock Option (right to buy) Disposition 2021-01-15 29,273 $0.00 29,273 $1.01
Common Stock Employee Stock Option (right to buy) Disposition 2021-01-19 5,727 $0.00 5,727 $1.01
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
108,203 2025-11-01 No 4 M Direct
78,930 2025-11-01 No 4 M Direct
73,203 2025-11-01 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 14, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
  2. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.88 to $43.86. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.76. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  4. Following the sales reported on this Form 4, the reporting person continues to beneficially own 175,994 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 458,852 shares of the Issuer's common stock, 284,936 of which are exercisable as of the date hereof. The original Form 4 filed on January 19, 2021 is being amended by this Form 4 solely to correct an administrative error, which misreported the total number of options held by the reporting person and the amount exercisable as of January 19, 2021.
  5. The reporting person was granted an option to purchase 149,203 shares of the Issuer's common stock on November 1, 2015. All of the shares underlying such stock option have vested and are exercisable as of the date hereof.